APA (7th ed.) Citation

Bischoff, J., Barinoff, J., Mundhenke, C., Bauerschlag, D. O., Costa, S., Herr, D., . . . Loibl, S. (2019). A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). Anti-cancer drugs, 30(4), . https://doi.org/10.1097/CAD.0000000000000722

Chicago Style (17th ed.) Citation

Bischoff, Joachim, et al. "A Randomized Phase II Study to Determine the Efficacy and Tolerability of Two Doses of Eribulin Plus Lapatinib in Trastuzumab-pretreated Patients with HER-2-positive Metastatic Breast Cancer (E-VITA)." Anti-cancer Drugs 30, no. 4 (2019). https://doi.org/10.1097/CAD.0000000000000722.

MLA (9th ed.) Citation

Bischoff, Joachim, et al. "A Randomized Phase II Study to Determine the Efficacy and Tolerability of Two Doses of Eribulin Plus Lapatinib in Trastuzumab-pretreated Patients with HER-2-positive Metastatic Breast Cancer (E-VITA)." Anti-cancer Drugs, vol. 30, no. 4, 2019, https://doi.org/10.1097/CAD.0000000000000722.